Maja Bujas‐Bobanovic

Author

Also Known As

Bujas-Bobanovic M., Bujas-Bobanovic, Maja, M Bujas‐Bobanovic, M. Bujas-Bobanovic, M. Bujas‐Bobanovic, Maja Bujas-Bobanovic, Maja Bujas‐Bobanovic

Publications

982

Citations

H-Index

Concepts

All Affiliations

Sanofi (France)Regeneron (United States)University of Toronto Imperial College London St. Michael's Hospital

About

Maja Bujas‐Bobanovic is an author at Sanofi (France) specializing in medicine, pharmacology, and oxidative stress.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	4	4	111
2	Public Health	1	1	14
3	Social Sciences	1	1	49
4	Biochemistry	1	1	30
5	Diabetes	1	1	14

Maja Bujas‐Bobanovic

Publications

933

Citations

H-Index

Page 1

	Year	Citations
Efficacy and safety of alirocumab in insulin‐treated individuals with type 1 or type 2 diabetes and high cardiovascular risk: The <scp>ODYSSEY DM‐INSULIN</scp> randomized trial Lawrence A. Leiter, Bertrand Cariou, Dirk Müller‐Wieland, Diabetes Obesity and Metabolism	2017	136
Alirocumab vs usual lipid‐lowering care as add‐on to statin therapy in individuals with type 2 diabetes and mixed dyslipidaemia: The ODYSSEY DM‐DYSLIPIDEMIA randomized trial Kausik K. Ray, Lawrence A. Leiter, Dirk Müller‐Wieland, Diabetes Obesity and Metabolism	2018	94
Blockade of phencyclidine‐induced effects by a nitric oxide donor Maja Bujas‐Bobanovic, David C. Bird, H.A. Robertson, British Journal of Pharmacology	2000	86
Game-based versus traditional case-based learning: comparing effectiveness in stroke continuing medical education. Deanna Telner, Maja Bujas‐Bobanovic, David W. Chan, PubMed	2010	84
Lipoprotein(a) reductions from PCSK9 inhibition and major adverse cardiovascular events: Pooled analysis of alirocumab phase 3 trials Kausik K. Ray, Antonio J. Vallejo‐Vaz, Henry N. Ginsberg, Atherosclerosis	2019	66
Lack of phencyclidine-induced effects in mice with reduced neuronal nitric oxide synthase Diane Bird, Maja Bujas‐Bobanovic, H.A. Robertson, Psychopharmacology Molecular PharmacologyMolecular NeuroscienceNeurophysiologyMedicineReactive Nitrogen Specie	2001	49
Lipid‐lowering efficacy and safety of alirocumab in patients with or without diabetes: <scp>A</scp> sub‐analysis of <scp>ODYSSEY COMBO II</scp> Lawrence A. Leiter, José Luis Zamorano, Maja Bujas‐Bobanovic, Diabetes Obesity and Metabolism	2017	49
Alirocumab therapy in individuals with type 2 diabetes mellitus and atherosclerotic cardiovascular disease: analysis of the ODYSSEY DM-DYSLIPIDEMIA and DM-INSULIN studies Kausik K. Ray, Stefano Del Prato, Dirk Müller‐Wieland, Cardiovascular Diabetology	2019	45
Transiently achieved very low LDL-cholesterol levels by statin and alirocumab after acute coronary syndrome are associated with cardiovascular risk reduction: the ODYSSEY OUTCOMES trial Gregory G. Schwartz, Michael Szarek, Deepak L. Bhatt, European Heart Journal	2023	43
Patient and Physician Perspectives on Mode of Administration of the PCSK9 Monoclonal Antibody Alirocumab, an Injectable Medication to Lower LDL-C Levels Eli M. Roth, Maja Bujas‐Bobanovic, Michael J. Louie, Clinical Therapeutics	2015	38

Page 1